AEMD stock forecast, quote, news & analysis
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression... Show more
Aethlon Medical (AEMD) Stock Analysis: Final Hemopurifier Cohort Progress Meets Dilution Pressure
Key Takeaways
- AEMD shares traded near $2.49 as of late August 2026, roughly 6% below levels from 30 days earlier — a comparatively contained move relative to the stock's longer-term decline.
- Aethlon Medical is a clinical-stage, pre-revenue micro-cap developing the Hemopurifier, an investigational device designed to remove tumor-derived extracellular vesicles and enveloped viruses from circulation.
- The Australian Phase 1 oncology trial advanced into its final dosing cohort, with preliminary biomarker signals described as supportive but still early.
- A 1-for-5 reverse stock split took effect in early August 2026 to support Nasdaq minimum-bid compliance, following a $4.0 million follow-on offering completed in July.
- Analysts at H.C. Wainwright and Maxim Group maintain neutral (Hold) ratings, reflecting balanced clinical progress against ongoing cash burn and dilution risk.
Current Market Snapshot
Aethlon Medical's shares have drifted modestly lower over the trailing 30 days, falling from about $2.66 to roughly $2.49 — a decline of approximately 6% on a split-adjusted basis. That compares with a far more severe contraction over the trailing 12 months, during which the stock has fallen more than 90% and trades well below its 52-week high. With a market capitalization of only about $1.8 million and a nine-person workforce, AEMD is an exceptionally small, thinly traded security, and its price action can be punctuated by sharp single-session swings and elevated volatility.
The recent 30-day period coincided with the completion of a reverse stock split and a follow-on equity offering, both of which shape how investors interpret the company's valuation and capital structure. While the shares stabilized after the split, the company's pre-revenue status and reliance on equity financing continue to define the broader sentiment backdrop.
Aethlon Medical (AEMD) Business Overview and Competitive Position
Aethlon Medical is a San Diego-based medical device company advancing the Hemopurifier, an investigational extracorporeal blood-filtration cartridge. The device uses a proprietary plant lectin (GNA) affinity resin to bind and remove tumor-derived extracellular vesicles (EVs) and enveloped viruses from circulating plasma, and it is designed to work with existing dialysis and continuous renal replacement therapy machines already present in hospitals worldwide.
The Hemopurifier holds U.S. Food and Drug Administration Breakthrough Device designation for two indications: the treatment of advanced or metastatic cancer in patients unresponsive to or intolerant of standard-of-care therapy, and the treatment of life-threatening viruses not addressed by approved therapies. Oncology is the company's lead program, with additional exploratory work in infectious disease, organ transplantation, and long COVID. Because Aethlon is pre-revenue and has no marketed products, its investment case centers almost entirely on clinical data, regulatory milestones, and its ability to fund continued development.
Recent Developments Driving AEMD
The most consequential clinical update came with Aethlon's fiscal Q1 2027 results and business update. The company reported that its Australian Phase 1 safety and dose-finding study in solid-tumor patients advanced to the final cohort, with the first participant dosed at Royal North Shore Hospital. The independent Data Safety Monitoring Board cleared progression from Cohort 2, citing no device-related serious adverse events or dose-limiting toxicities. Management described early observations from the first two cohorts as showing decreases in cancer-associated EVs and microRNAs alongside improvements in immune function, while repeatedly cautioning that the data remain preliminary.
Financially, the company reported that consolidated operating expenses fell roughly 12% year over year, narrowing its operating loss, with cash and equivalents of approximately $4.9 million as of June 30, 2026. A post-quarter public offering added about $4.0 million in gross proceeds, and management has stated that current resources are sufficient to fund operations for at least 12 months under existing plans.
These developments were accompanied by significant capital-structure changes. The company completed a $4.0 million follow-on offering in July 2026 and implemented a 1-for-5 reverse stock split effective August 4, 2026, citing continued compliance with Nasdaq's minimum-bid-price listing rule. Analysts have responded cautiously: H.C. Wainwright reiterated a Neutral rating with a $1.50 price target, while Maxim Group maintained a Hold, citing balanced risk-reward given pre-revenue status and ongoing cash burn.
Trending AI Robots
For investors seeking a data-driven complement to manual stock analysis, Tickeron's Trending AI Robots page curates a selection of AI-powered trading bots. Tickeron offers hundreds of AI trading bots that collectively monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary considerably in strategy, timeframe, and performance metrics, giving traders a range of approaches to evaluate. The section is designed to help users quickly identify algorithms that are currently generating notable results. Exploring the available bots can offer additional perspective for those looking to supplement their own research with automated, rules-based signals.
2026 Outlook and What Investors Should Watch
The primary catalyst for AEMD in the coming months is completion of the Australian oncology trial. Management aims to finish dosing the remaining participants and complete the eight-week follow-up period, then analyze the full data set and pursue pre-registration discussions with regulators such as the FDA and Australia's Therapeutic Goods Administration. Favorable results could support progression toward an efficacy study and, potentially, a partnership to help fund later-stage development.
Investors should also monitor the company's capital position. Beyond the stated 12-month runway, additional financing is likely to be required to advance the Hemopurifier further, and future equity raises could carry dilution risk. A shareholder vote scheduled for October 2026 proposes, among other items, an increase in authorized common stock — a measure that underscores the company's continuing reliance on equity financing. Nasdaq listing compliance, cash-burn trajectory, and any new safety or efficacy data remain key variables. As with any clinical-stage, pre-revenue company, the path to commercialization carries substantial regulatory and execution uncertainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AEMD's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Oscillator for AEMD moved out of overbought territory on August 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEMD as a result. In of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
AEMD moved below its 50-day moving average on August 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AEMD crossed bearishly below the 50-day moving average on August 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEMD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for AEMD entered a downward trend on September 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for AEMD just turned positive on September 03, 2026. Looking at past instances where AEMD's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .
AEMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.249) is normal, around the industry mean (10.956). P/E Ratio (0.009) is within average values for comparable stocks, (69.665). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.707). AEMD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (2.111) is also within normal values, averaging (40.034).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AEMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of diagnostic and therapeutic device solutions for infectious disease, cancer and for other life threatening conditions
Industry MedicalNursingServices